Metabolic dysfunction is associated with steatosis but no other histologic features in nonalcoholic fatty liver disease

Figure 2 Comparison of histologic features and the presence of nonalcoholic steatohepatitis and significant fibrosis in the metabolic-associated fatty liver disease and non-metabolic-associated fatty liver disease subgroups of nonalcoholic fatty liver disease, obese nonalcoholic fatty liver disease and lean nonalcoholic fatty liver disease, nonalcoholic fatty liver disease according to glycemia, and nonalcoholic fatty liver disease according to liver function. A: Steatosis grade (P = 0.007 in the comparison between metabolic-associated fatty liver disease (MAFLD) and non-MAFLD; P = 0.007 in the comparison between obese and lean nonalcoholic fatty liver disease (NAFLD); P = 0.260 in the comparison among normal glycemia, prediabetes and type 2 diabetes mellitus (T2DM); P < 0.001 in the comparison among normal liver function, increased liver enzyme levels, and liver injury); B: Lobular inflammation (P = 0.461 in the comparison between MAFLD and non-MAFLD; P = 0.247 in the comparison between obese and lean NAFLD; P = 0.400 in the comparison among normal glycemia, prediabetes and T2DM; P = 0.496 in the comparison among normal liver function, increased liver enzyme levels and liver injury); C: Portal inflammation (P = 0.091 in the comparison between MAFLD and non-MAFLD; P = 0.003 in the comparison between obese and lean NAFLD; P = 0.676 in the comparison among normal glycemia, prediabetes, and T2DM; P = 0.190 in the comparison among normal liver function, increased liver enzyme levels, and liver injury); D: Balloon degeneration (P = 0.251 in the comparison between MAFLD and non-MAFLD; P = 0.116 in the comparison between obese and lean NAFLD; P = 0.717 in the comparison among normal glycemia, prediabetes, and T2DM; P = 0.021 in the comparison among normal liver function, increased liver enzyme levels, and liver injury); E: Fibrosis grade (P = 0.151 in the comparison between MAFLD and non-MAFLD; P = 0.250 in the comparison between obese and lean NAFLD; P = 0.563 in the comparison among normal glycemia, prediabetes, and T2DM; P = 0.223 in the comparison among normal liver function, increased liver enzyme levels, and liver injury); F: Presence of nonalcoholic steatohepatitis (P = 0.228 in the comparison between MAFLD and non-MAFLD; P = 0.098 in the comparison between obese and lean NAFLD; P = 0.849 in the comparison among normal glycemia, prediabetes, and T2DM; P = 0.001 in the comparison among normal liver function, increased liver enzyme levels, and liver injury); G: Presence of significant fibrosis (P = 0.749 in the comparison between MAFLD and non-MAFLD; P = 1.000 in the comparison between obese and lean NAFLD; P = 0.357 in the comparison among normal glycemia, prediabetes, and T2DM; P = 0.097 in the comparison among normal liver function, increased liver enzyme levels, and liver injury); H: NAFLD activity score (3.11 ± 1.29 in MAFLD vs 2.41 ± 0.67 in non-MAFLD, P = 0.002; 3.16 ± 1.32 in obese NAFLD vs 2.44 ± 0.70 in lean NAFLD, P = 0.002; 2.83 ± 1.08, 3.00 ± 1.39, and 3.20 ± 1.23 in normal glycemia, prediabetes, and T2DM, respectively, overall P = 0.141; 2.50 ± 1.00, 2.70 ± 1.01, and 3.89 ± 1.37 in normal liver function, increased liver enzyme levels, and liver injury, respectively, overall P < 0.001). T2DM: Type 2 diabetes mellitus; NAFLD: Nonalcoholic fatty liver disease; MAFLD: Metabolic-associated fatty liver disease; NASH: Nonalcoholic steatohepatitis.